看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
" y3 m u& G2 h/ s7 M7 F; L
4 N1 I8 z, g+ z! _5 J& X2 j7 U: T& v1 l& q% C; C5 J5 N
Currently available feasibility data for possible combination strategies. 1 y v/ ?; A& @7 b
————————————————————————————————& ^6 D+ Z' H+ \8 \' U
Combination Feasibility according to preliminary data
# m% j% I, e& q% _: k——————————————————————————————————, `1 P% a4 c" Q5 A* a
Bevacizumab + sorafenib Yes, reduced dose 1 s4 W: e9 u, ^4 I7 d, w
Bevacizumab + sunitinib† No 4 S @2 I* f" _, g+ ^7 |
Bevacizumab + temsirolimus Yes
9 z8 [$ ?+ {; i/ [; j2 yBevacizumab + everolimus Yes
) ^: D7 @( Y8 D% qSorafenib + sunitinib ? $ z- U" o3 K* t$ L/ U1 q* u9 j
Sorafenib + temsirolimus Yes, reduced dose 9 h V8 Y) x% ~3 d
Sorafenib + everolimus Yes, reduced dose
" ~$ Z; u, L% ]3 v- eSunitinib + temsirolimus† No
, e* S) R3 |3 Q' r5 cSunitinib + everolimus ? ( T6 A* X; @0 @. g+ F
Temsirolimus + everolimus ?
, p( M0 A" ]4 a0 i0 e+ a7 t$ S8 b————————————————————7 `# g P6 C$ R" n8 n' L' Y. x% p
†Led to US FDA warning.+ _1 T: r( M0 P6 W$ h
?: As yet unattempted combination.0 R& W. A8 v* N. E8 E* R
|